KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update

–U.S. FDA accepts NDA for sebetralstat for oral on-demand treatment of HAE; Sets PDUFA goal date of June 17, 2025–

–European Medicines Agency (EMA) validated the submission of Marketing Authorization Application (MAA) for sebetralstat–

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today provided an operational update and released financial results for the first fiscal quarter ended July 31, 2024.

“We are excited about the steady progress we’ve made over the last few months including the most recent acceptance of our NDA by FDA and the EMA’s validation of our MAA,” said Ben Palleiko, CEO of KalVista. “We look forward to building on these recent milestones as we move toward filing for approval in the UK, Japan, and other countries later in 2024 and aim for our first commercial launch of sebetralstat in June 2025. I am grateful for the hard work of the entire KalVista team as we remain dedicated to getting this important treatment to people living with HAE.”

First Fiscal Quarter and Recent Business Highlights:

Sebetralstat

• In September, KalVista announced the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for sebetralstat, a novel, investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) attacks in adult and pediatric patients aged 12 years and older. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of June 17, 2025.
• Last month, the Company announced that the European Medicines Agency (EMA) validated the submission of the Marketing Authorization Application (MAA) for sebetralstat.
• KalVista expects to file for approval in the UK, Japan, and other countries later in 2024. The Company has also engaged with the Access Consortium to maximize regulatory collaboration across countries and support a timely review process.
• In June, ahead of schedule, KalVista initiated a pediatric clinical trial (KONFIDENT-KID) using an orally disintegrating tablet (ODT) formulation of sebetralstat designed for this population. KONFIDENT-KID will enroll approximately 24 children, with an age range of 2 to 11 years, across seven countries in North America, Europe and Asia. The trial has since started dosing patients and if approved, sebetralstat would be the first oral, on demand treatment for this population and only the second approved on-demand therapy of any type.
• Data from the phase 3 KONFIDENT trial of sebetralstat was published in the New England Journal of Medicine (NEJM) and presented at the European Academy of Allergy and Clinical Immunology Congress 2024 (EAACI).

First Fiscal Quarter Financial Results

• Revenue: No revenue was recognized for the three months ended July 31, 2024, or July 31, 2023, respectively.
• R&D Expenses: Research and development expenses were $26.6 million for the three months ended July 31, 2024, compared to $19.3 million for the same period in the prior fiscal year. The increase in R&D expenses during the quarter primarily reflects the phase 3 KONFIDENT trial which concluded in February 2024, the ongoing KONFIDENT-S trial, and a headcount driven increase in personnel costs.
• G&A Expenses: General and administrative expenses were $17.6 million for the three months ended July 31, 2024, compared to $9.8 million for the same period in the prior fiscal year. The increase in G&A expenses was primarily due to increases in commercial planning expenses and employee-related expenses.
• Net Loss: Net loss was $40.4 million, or $(0.87) per weighted average basic and diluted share, for the three months ended July 31, 2024, compared to net loss of $25.3 million, or $(0.74) per weighted average basic and diluted share for the same period in the prior fiscal year. The increase in net loss and net loss per share primarily resulted from the increase in operating expenses, both research and development and general and administrative.
• Cash position: Cash, cash equivalents and marketable securities were $174.3 million on July 31, 2024, compared to $210.4 million on April 30, 2024. The decrease in the net cash and marketable securities position was due to cash consumption from operating expenses.

About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. is a global pharmaceutical company focused on the development and delivery of oral medicines for diseases with significant unmet need. KalVista announced positive phase 3 data from the KONFIDENT trial for its oral, on-demand therapy, sebetralstat for HAE in February 2024. The Company’s NDA for sebetralstat has been accepted by the FDA with a PDUFA goal date of June 17, 2025. KalVista received validation of its MAA from the EMA in August 2024. KalVista expects to file for approval in the UK, Japan, and other countries later in 2024.

For more information about KalVista, please visit www.kalvista.com or follow on social media at @KalVista and LinkedIn.

Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our KONFIDENT-S and KONFIDENT-KID trials, and to obtain regulatory approvals for sebetralstat and other candidates in development, the success of any efforts to commercialize sebetralstat, the ability of sebetralstat and other candidates in development to treat HAE or other diseases, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2024, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

KalVista Pharmaceuticals Inc.
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
(Unaudited)
	July 31,			April 30,
		2024			2024
Assets
Current assets:
Cash and cash equivalents	$	31,848		$	31,789
Marketable securities		142,424			178,612
Research and development tax credit receivable		9,908			8,439
Prepaid expenses and other current assets		7,454			6,850
Total current assets		191,634			225,690
Property and equipment, net		2,100			2,227
Right of use assets		5,859			6,920
Other assets		605			567
Total assets	$	200,198		$	235,404
Liabilities and stockholders' equity
Current liabilities:
Accounts payable	$	10,792		$	9,107
Accrued expenses		10,355			12,398
Lease liability - current portion		1,264			1,302
Total current liabilities		22,411			22,807
Long-term liabilities:
Lease liability - net of current portion		4,988			6,015
Total long-term liabilities		4,988			6,015
Stockholders’ equity:
Common stock, $0.001 par value		43			42
Additional paid-in capital		685,794			679,754
Accumulated deficit		(510,169	)		(469,726	)
Accumulated other comprehensive loss		(2,869	)		(3,488	)
Total stockholders’ equity		172,799			206,582
Total liabilities and stockholders' equity	$	200,198		$	235,404

KalVista Pharmaceuticals Inc.
Condensed Consolidated Statement of Operations
(in thousands, except share and per share amounts)
(Unaudited)
	Three Months Ended
	July 31,
		2024			2023
Revenue	$	—		$	—
Operating expenses:
Research and development		26,614			19,307
General and administrative		17,601			9,786
Total operating expenses		44,215			29,093
Operating loss		(44,215	)		(29,093	)
Other income:
Interest income		1,692			923
Foreign currency exchange gain		514			456
Other income		1,566			2,397
Total other income		3,772			3,776
Net loss	$	(40,443	)	$	(25,317	)
Net loss per share, basic and diluted	$	(0.87	)	$	(0.74	)
Weighted average common shares outstanding, basic and diluted		46,232,977			34,414,226

KalVista Pharmaceuticals Inc.
Condensed Consolidated Statements of Cash Flows
(in thousands, unaudited)
	Three Months Ended
	July 31,
		2024			2023
Cash flows from operating activities
Net loss	$	(40,443	)	$	(25,317	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		224			193
Stock-based compensation expense		3,040			3,254
Realized gain from sale of marketable securities		(317	)		(314	)
Non-cash operating lease (benefit) expense		(5	)		6
Amortization of premium on marketable securities		5			62
Foreign currency exchange gain		(414	)		(395	)
Changes in operating assets and liabilities:
Research and development tax credit receivable		(1,253	)		(2,084	)
Prepaid expenses and other current assets		(783	)		(1,003	)
Accounts payable		1,502			108
Accrued expenses		(1,776	)		(1,240	)
Net cash used in operating activities		(40,220	)		(26,730	)
Cash flows from investing activities
Purchases of marketable securities		(983	)		(25,767	)
Sales and maturities of marketable securities		38,230			45,386
Acquisition of property and equipment		(21	)		(6	)
Capitalized website development costs		(64	)		-
Net cash provided by investing activities		37,162			19,613
Cash flows from financing activities
Issuance of common stock from equity incentive plans		3,000			204
Net cash provided by financing activities		3,000			204
Effect of exchange rate changes on cash and cash equivalents		117			84
Net increase (decrease) in cash and cash equivalents		59			(6,829	)
Cash and cash equivalents at beginning of period		31,789			56,238
Cash and cash equivalents at end of period	$	31,848		$	49,409